Accuray (ARAY) Q4 2026 earnings review
Cost Cuts Mask a Top-Line Collapse
Accuray ended FY2026 with a severe deceleration in its core hardware business. Q4 product revenue collapsed 42% YoY, and gross orders plunged 55%. Despite this top-line bleed, Adjusted EBITDA actually reversed upward to $12.9M (from $9.4M a year ago). This profitability mirage was purely driven by management's aggressive transformation plan, which gutted operating expenses by 15% and delivered $20M+ in annualized savings. However, you cannot shrink your way to long-term growth. With order backlog down 27% and management refusing to provide FY27 guidance due to geopolitical and tariff uncertainties, the foundation of the business looks highly unstable.
🐂 Bull Case
The internal transformation plan delivered over $20 million in cost and margin improvements, crushing the initial $12 million target and proving management can execute on operational efficiency.
Service revenue grew 6% YoY to $60.1M, creating a highly profitable recurring revenue floor that is insulating the bottom line from hardware volatility.
🐻 Bear Case
Gross product orders fell off a cliff, dropping 55% YoY to $37.7M. The 0.9 book-to-bill ratio signals that Accuray is burning through its backlog faster than it can replace it.
Management entirely pulled formal FY27 revenue and EBITDA guidance, citing China, Middle East disruptions, and tariffs. This confirms a severe lack of operational predictability.
⚖️ Verdict: 🔴
Bearish. While management deserves credit for rightsizing the cost structure and improving liquidity, the underlying capital equipment business is decelerating at an alarming rate. Refusal to provide FY27 guidance leaves investors flying blind into a shrinking backlog.
Key Themes
Capital Equipment Orders Decelerating Rapidly
The most concerning data point in the Q4 release is the complete collapse of forward-looking demand. Gross product orders dropped to $37.7 million, down 55% from $84.7 million in 25Q4. Order backlog has steadily deteriorated throughout FY26, landing at $312.5 million—a 27% YoY decline. Management's claim that they enter FY27 from a 'position of greater strength' directly contradicts the reality of a rapidly shrinking order pipeline.
Transformation Plan Execution Drives Profitability
Accuray successfully reversed its EBITDA margin trajectory through aggressive restructuring. Operating expenses fell 15% YoY to $29.6 million (and would have dropped 17% excluding $0.7M in restructuring charges). The transformation plan yielded over $20 million in annualized savings, heavily outperforming the initial $12 million target. This disciplined cost control is the sole reason the company reported $12.9 million in Adjusted EBITDA despite a 21% plunge in total revenue.
Service Mix Shift Buoys Gross Margins
Service revenue was stable and growing, rising 6% YoY in Q4 to $60.1 million. Because product sales cratered, services now make up roughly 60% of total revenue, up from 45% a year ago. Because services carry structurally higher margins, this mix shift artificially lifted total gross profit margin to 34.8% from 30.6% YoY. Management explicitly targets further service margin improvement via 'pricing optimization and operational efficiencies' moving into FY27.
Macro Picture: Geopolitics and Tariffs Freeze Deals
The macroeconomic environment remains hostile to Accuray's capital equipment cycle. The company cited ongoing uncertainty related to 'international trade policy, tariff impacts, conditions in China and the Middle East.' This is a continuation of Q3's theme where indefinite shipment delays to the Middle East and North Africa disrupted revenue. The inability to navigate these external shocks ultimately forced management to pull FY27 guidance entirely.
Shift to Ecosystem Partnerships
Unable to outspend larger competitors on R&D, Accuray is leaning heavily into strategic partnerships (e.g., Tata Consultancy Services, UW-Madison) to advance its adaptive therapy and imaging software. This is a capital-efficient way to accelerate innovation, keeping internal R&D expenses suppressed while still bringing differentiated technologies to the installed base.
Other KPIs
Accelerating significantly from 30.6% a year ago. However, this is largely a mathematical illusion created by the 42% collapse in lower-margin product revenue. Service revenues, which carry higher margins, became a much larger piece of the overall revenue pie.
Reversing positively from $9.4 million a year ago. Q4 represented the strongest EBITDA quarter of the year, underscoring the raw effectiveness of the workforce reductions and discretionary spend cuts implemented in Q2 and Q3.
Stable sequentially, up $2.7 million from March 31. The new comprehensive financing transaction with TCW Asset Management provides crucial covenant relief through December 2027 and reduces immediate leverage pressure during this operational turnaround.
Guidance
Management refused to provide formal revenue or Adjusted EBITDA guidance for the upcoming fiscal year. This is a severe red flag indicating a total lack of visibility into the timing of capital equipment orders in China and the Middle East.
Key Questions
Visibility into the Backlog
With the backlog shrinking 27% to $312 million, what percentage of these remaining orders are currently paused or at risk of cancellation due to the ongoing geopolitical freeze in the Middle East and China?
Limits of Cost Cutting
You significantly exceeded the $12M transformation savings target by achieving $20M+ in FY26. Have we reached the bottom on operating expenses, or are there more cuts planned to defend EBITDA if product revenue continues to decline?
Conditions for Guidance Reinstatement
You withdrew formal FY27 guidance due to macro uncertainty. What specific stabilization metrics or geopolitical developments do you need to see before you feel comfortable reinstating financial targets for the market?